{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:48:53Z","timestamp":1788241733341,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00702-021-02339-7","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T18:34:51Z","timestamp":1618943691000},"page":"521-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dystonia and leveraging oral pharmacotherapy"],"prefix":"10.1007","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-7569","authenticated-orcid":false,"given":"Michelle Ann C.","family":"Sy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"2339_CR1","first-page":"1405","volume":"9","author":"A Adler","year":"1993","unstructured":"Adler A, Peselow E, Rotrosen J, Duncan E, Angrist B (1993) Brief reports vitamin. Biol Psychiatry 9:1405\u20131407","journal-title":"Biol Psychiatry"},{"key":"2339_CR2","first-page":"134","volume":"19","author":"LA Adler","year":"1998","unstructured":"Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M et al (1998) Long-term treatment effects of vitamin e for tardive dyskinesia. Biol Psychiatry 19:134\u2013138","journal-title":"Biol Psychiatry"},{"key":"2339_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1468-1331.2006.01537.x","volume":"26","author":"MA Albanese","year":"2006","unstructured":"Albanese MA, Barnes MP, Bhatia KP, Fernandez-alvarez E (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS\/MDS-ES Task Force. Eur J Neurol 26:433\u2013444","journal-title":"Eur J Neurol"},{"key":"2339_CR4","first-page":"5","volume":"1","author":"A Albanese","year":"2009","unstructured":"Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G et al (2009) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 1:5\u201318","journal-title":"Eur J Neurol"},{"issue":"1","key":"2339_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ene.13762","volume":"26","author":"A Albanese","year":"2019","unstructured":"Albanese A, Di Giovanni M, Lalli S (2019) Dystonia: diagnosis and management. Eur J Neurol 26(1):5\u201317","journal-title":"Eur J Neurol"},{"key":"2339_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678707.2017.1366309","volume":"6","author":"I Alfradique-dunham","year":"2017","unstructured":"Alfradique-dunham I, Jankovic J, Alfradique-Dunham I, Jankovic J (2017) Expert opinion on orphan drugs available treatment options for dystonia available treatment options for dystonia. Expert Opin Orphan Drugs [Internet] 6:1\u201310. https:\/\/doi.org\/10.1080\/21678707.2017.1366309","journal-title":"Expert Opin Orphan Drugs [Internet]"},{"issue":"5","key":"2339_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/08830738030180050701","volume":"18","author":"MH Anca","year":"2003","unstructured":"Anca MH, Zaccai TF, Badarna S, Lozano AM, Lang AE, Giladi N (2003) Natural history of oppenheim \u2019 s dystonia (DYT1) in Israel. J Child Neurol 18(5):325\u2013330","journal-title":"J Child Neurol"},{"issue":"17","key":"2339_CR8","first-page":"1","volume":"366","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoj\u00e4rvi J et al (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia ( AIM-TD ): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psyc 366(17):1\u201310","journal-title":"Lancet Psyc"},{"issue":"1","key":"2339_CR9","first-page":"65","volume":"19","author":"R Ankenman","year":"2007","unstructured":"Ankenman R, Salvatore MF (2007) Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. J NeuropsycClinNeurosci 19(1):65\u201369","journal-title":"J NeuropsycClinNeurosci"},{"issue":"4","key":"2339_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1186\/s40734-016-0047-6","volume":"24","author":"R Ankenman","year":"2014","unstructured":"Ankenman R, Salvatore MF, Burke RE, Fahn S, Marsden CD et al (2014) Treatment of dystonia. MovDisord [Internet] 24(4):724\u2013732. https:\/\/doi.org\/10.1186\/s40734-016-0047-6","journal-title":"MovDisord [Internet]"},{"key":"2339_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/bs.irn.2017.05.003","volume":"134","author":"J Ann","year":"2017","unstructured":"Ann J, Torres KL, Rosales RL (2017) Nonmotor symptoms in dystonia. Internat Rev Neurobiol 134:1335\u20131371","journal-title":"Internat Rev Neurobiol"},{"key":"2339_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2019.00779","volume":"10","author":"SPJ Badillo","year":"2019","unstructured":"Badillo SPJ, Jamora RDG (2019) Zolpidem for the treatment of dystonia. Front Neurol 10:1\u20137","journal-title":"Front Neurol"},{"key":"2339_CR13","first-page":"213","volume":"2","author":"A Batla","year":"2012","unstructured":"Batla A (2012) Neurology DM. Treat Focal Dystonia 2:213\u2013229","journal-title":"Treat Focal Dystonia"},{"issue":"2","key":"2339_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/01.nrl.0000195831.46000.2d","volume":"12","author":"R Bhidayasiri","year":"2006","unstructured":"Bhidayasiri R (2006) Dystonia: genetics and treatment update. Neurologist 12(2):74\u201385","journal-title":"Neurologist"},{"key":"2339_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","volume":"389","author":"R Bhidayasiri","year":"2018","unstructured":"Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S (2018) Journal of the neurological sciences updating the recommendations for treatment of tardive syndromes\u202f: a systematic review of new evidence and practical treatment algorithm. J NeurolSci 389:67\u201375. https:\/\/doi.org\/10.1016\/j.jns.2018.02.010","journal-title":"J NeurolSci"},{"issue":"12","key":"2339_CR16","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/mds.26330","volume":"30","author":"CFO Brien","year":"2015","unstructured":"Brien CFO, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D et al (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia\u202f: a randomized, double-blind, placebo-controlled study. Move Dis 30(12):1681\u20131687","journal-title":"Move Dis"},{"issue":"2","key":"2339_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1212\/WNL.36.2.160","volume":"36","author":"RE Burke","year":"1986","unstructured":"Burke RE, Fahn S, Marsden CD (1986) Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36(2):160\u2013164","journal-title":"Neurology"},{"issue":"6","key":"2339_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1371\/journal.pone.0065215","volume":"8","author":"C Cai","year":"2013","unstructured":"Cai C, Shi W, Zeng Z, Zhang M, Ling C, Chen L et al (2013) GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in familial and sporadic dopa-responsive dystonia patients. PLoS ONE 8(6):4\u20138","journal-title":"PLoS ONE"},{"key":"2339_CR19","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.parkreldis.2017.06.025","volume":"46","author":"CL Comella","year":"2015","unstructured":"Comella CL (2015) Dystonia: then and now. Park RelatDisord 46:S66\u2013S69. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.06.025","journal-title":"Park RelatDisord"},{"issue":"1","key":"2339_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1013-9","volume":"14","author":"R De Silva","year":"2019","unstructured":"De Silva R, Greenfield J, Cook A, Bonney H, Vallortigara J, Hunt B et al (2019) Guidelines on the diagnosis and management of the progressive ataxias. Orphanet J Rare Dis 14(1):1\u201310","journal-title":"Orphanet J Rare Dis"},{"key":"2339_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1056\/NEJM197110072851516","volume":"285","author":"BL Decker","year":"1971","unstructured":"Decker BL, Davis J, Janowsky DS, El Yousef K, Sekerke HJ (1971) Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med 285:860","journal-title":"N Engl J Med"},{"key":"2339_CR22","first-page":"221","volume":"12","author":"CCS Delnooz","year":"2012","unstructured":"Delnooz CCS, Van De WBPC (2012) Current and future medical treatment in primary dystonia. TheraAdvNeurol Dis 12:221\u2013240","journal-title":"TheraAdvNeurol Dis"},{"key":"2339_CR23","first-page":"523","volume":"17","author":"RL Dufresne","year":"1978","unstructured":"Dufresne RL, Becker RE, Mastrati P (1978) Diazepam in tardive dyskinesia. Move Dis 17:523\u2013527","journal-title":"Move Dis"},{"issue":"3","key":"2339_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1017\/S0317167100038051","volume":"14","author":"S Fahn","year":"1987","unstructured":"Fahn S (1987) Systemic therapy of dystonia. Can J NeurolSci 14(3):528\u2013532","journal-title":"Can J NeurolSci"},{"issue":"6","key":"2339_CR25","first-page":"467","volume":"11","author":"HH Fernandez","year":"1999","unstructured":"Fernandez HH, Friedman JH (1999) The role of atypical antipsychotics in the treatment of movement disorders. Move Dis Soc 11(6):467\u2013483","journal-title":"Move Dis Soc"},{"key":"2339_CR26","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","volume":"7","author":"HH Fernandez","year":"2017","unstructured":"Fernandez HH, Meltzer HY, Woods SW, Bega D, Ledoux MS, Davis C et al (2017) Randomized controlled trial of deutetrabenazine for tardive dyskinesia The ARM-TD study. Neurology 7:2003\u20132010","journal-title":"Neurology"},{"key":"2339_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/ana.22685","volume":"123","author":"J Friedman","year":"2012","unstructured":"Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V et al (2012) Sepiapterin reductase deficiency\u202f: a treatable mimic of cerebral palsy. Ann Neurol 123:520\u2013530","journal-title":"Ann Neurol"},{"key":"2339_CR28","first-page":"1","volume":"2","author":"SJ Frucht","year":"2017","unstructured":"Frucht SJ (2017) Dystonic storm\u202f: a practical clinical and video review. Move Dis 2:1\u20138","journal-title":"Move Dis"},{"issue":"7","key":"2339_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"VSC Fung","year":"2013","unstructured":"Fung VSC, Hallett M, Jankovic J, Jinnah HA, Klein C (2013) Phenomenology and classification of dystonia: a consensus update. MovDisord 28(7):863\u2013873. https:\/\/doi.org\/10.1002\/mds.25475","journal-title":"MovDisord"},{"key":"2339_CR30","first-page":"7","volume":"15","author":"GJ Gilbert","year":"2015","unstructured":"Gilbert GJ, Petersburg S (2015) The medical treatment of spasmodic torticollis. Eur J Neurol 15:7\u201310","journal-title":"Eur J Neurol"},{"issue":"4","key":"2339_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF00432517","volume":"87","author":"WM Glazer","year":"1985","unstructured":"Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M (1985) The treatment of tardive dyskinesia with baclofen. Psychopharmacology 87(4):480\u2013483","journal-title":"Psychopharmacology"},{"key":"2339_CR32","first-page":"109","volume":"17","author":"S Gn","year":"2017","unstructured":"Gn S (2017) Case report management of oromandibulardystonia\u202f: a case report and literature update. Movement 17:109\u2013234","journal-title":"Movement"},{"issue":"4","key":"2339_CR33","first-page":"276","volume":"15","author":"P Greene","year":"1992","unstructured":"Greene P (1992) Baclofen in the treatment of dystonia. ClinNeuropharmacol 15(4):276\u2013288","journal-title":"ClinNeuropharmacol"},{"issue":"1","key":"2339_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/mds.870030107","volume":"3","author":"P Greene","year":"1988","unstructured":"Greene P, Shale H, Fahn S (1988) Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. J Move Dis Soc 3(1):46\u201360","journal-title":"J Move Dis Soc"},{"issue":"4","key":"2339_CR35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.amjopharm.2010.08.006","volume":"8","author":"DRP Guay","year":"2010","unstructured":"Guay DRP (2010) Tetrabenazine a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J GeriatrPharmacother [Internet] 8(4):331\u2013373. https:\/\/doi.org\/10.1016\/j.amjopharm.2010.08.006","journal-title":"Am J GeriatrPharmacother [Internet]"},{"key":"2339_CR36","first-page":"10","volume":"2","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Factor SA, Marder SR, Knesevich MA (2017) KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psyc 2:10\u201334","journal-title":"Am J Psyc"},{"key":"2339_CR37","first-page":"41","volume":"1","author":"J Jankovic","year":"1981","unstructured":"Jankovic J (1981) I reatment of hyperkmeac movement disorders with tetrabenazine\u202f: a double-blind crossover study. Ann Neurol 1:41\u201347","journal-title":"Ann Neurol"},{"issue":"10","key":"2339_CR38","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","volume":"5","author":"J Jankovic","year":"2006","unstructured":"Jankovic J (2006) Treatment of dystonia. Lancet Neurol 5(10):864\u2013872","journal-title":"Lancet Neurol"},{"issue":"1","key":"2339_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ncl.2014.09.002","volume":"33","author":"HA Jinnah","year":"2015","unstructured":"Jinnah HA (2015) Diagnosis and treatment of dystonia. NeurolClin NA 33(1):77\u2013100. https:\/\/doi.org\/10.1016\/j.ncl.2014.09.002","journal-title":"NeurolClin NA"},{"issue":"4","key":"2339_CR40","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1212\/CON.0000000000000747","volume":"25","author":"HA Jinnah","year":"2019","unstructured":"Jinnah HA (2019) TheDystonias. Contin Lifelong Learn Neurol 25(4):976\u20131000","journal-title":"Contin Lifelong Learn Neurol"},{"issue":"3","key":"2339_CR41","first-page":"8","volume":"47","author":"BRC Josiassen","year":"2007","unstructured":"Josiassen BRC, Kane JM, Liang GS, Burke J, Brien CFO (2007) Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia. Mood Dis 47(3):8","journal-title":"Mood Dis"},{"issue":"4","key":"2339_CR42","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/1531-8257(199907)14:4<652::AID-MDS1015>3.0.CO;2-G","volume":"14","author":"BI Karp","year":"1999","unstructured":"Karp BI, Goldstein SR, Chen R, Samii A, Bara-jimenez W, Hallett M (1999) An open trial of clozapine for dystonia. Move Dis Soc 14(4):652\u2013657","journal-title":"Move Dis Soc"},{"key":"2339_CR43","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/brain\/121.11.2053","volume":"1998","author":"V Kiriakakis","year":"1998","unstructured":"Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD (1998) The natural history of tardive dystonia A long-term follow-up study of 107 cases. Brain J Neurol 1998:2053\u20132066","journal-title":"Brain J Neurol"},{"key":"2339_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2217\/nmt-2018-0047","volume":"9","author":"KJ Lizarraga","year":"2019","unstructured":"Lizarraga KJ, Al-shorafat D, Fox S (2019) Update on current and emerging therapies for dystonia. Neurodegen dis manag 9:135\u2013147","journal-title":"Neurodegen dis manag"},{"issue":"6","key":"2339_CR45","first-page":"274","volume":"26","author":"N Lubarr","year":"2011","unstructured":"Lubarr N, Bressman S (2011) Treatment of generalized dystonia. Move Dis 26(6):274\u2013289","journal-title":"Move Dis"},{"issue":"12","key":"2339_CR46","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.parkreldis.2014.09.029","volume":"20","author":"AY Luciano","year":"2014","unstructured":"Luciano AY, Jinnah HA, Pfeiffer RF, Truong DD, Nance MA, Ledoux MS (2014) Treatment of myoclonus-dystonia syndrome with tetrabenazine. Park RelatDisord 20(12):1423\u20131426. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.029","journal-title":"Park RelatDisord"},{"key":"2339_CR47","first-page":"710","volume":"4","author":"RAH Ma","year":"2004","unstructured":"Ma RAH, Unit G (2004) Case report Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Develop Med Child Neurol 4:710\u2013712","journal-title":"Develop Med Child Neurol"},{"key":"2339_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.parkreldis.2018.12.022","volume":"59","author":"A Margolius","year":"2019","unstructured":"Margolius A, Fernandez HH (2019) Parkinsonism and related disorders current treatment of tardive dyskinesia. Park RelatDisord [Internet] 59:155\u2013160. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.12.022","journal-title":"Park RelatDisord [Internet]"},{"issue":"7","key":"2339_CR49","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/mds.21471","volume":"22","author":"P Mariotti","year":"2007","unstructured":"Mariotti P, Fasano A, Contarino MF, Della MG, Piastra M, Genovese O et al (2007) Management of status dystonicus: our experience and review of the literature. Move Dis 22(7):963\u2013968","journal-title":"Move Dis"},{"issue":"3","key":"2339_CR50","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.4088\/JCP.16m11049","volume":"78","author":"CL Mentzel","year":"2017","unstructured":"Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, Hoek HW, Tijssen MA, van Harten PN (2017) Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the cura\u00e7ao extrapyramidal syndromes study XII. J Clin Psychiatry 78(3):e279\u2013e285","journal-title":"J Clin Psychiatry"},{"key":"2339_CR51","first-page":"1","volume":"3","author":"Y Miyazaki","year":"2012","unstructured":"Miyazaki Y, Sako W, Asanuma K, Izumi Y, Miki T, Kaji R (2012) Efficacy of zolpidem for dystonia\u202f: a study among different subtypes. Front Neurol 3:1\u201358","journal-title":"Front Neurol"},{"key":"2339_CR52","first-page":"309","volume":"8","author":"Y Miyazaki","year":"2015","unstructured":"Miyazaki Y, Koizumi H, Miyamoto R, Kawarai T, Kaji R (2015) Treatment of isolated dystonia with zolpidem. Move Dis ClinPract 8:309\u2013311","journal-title":"Move Dis ClinPract"},{"issue":"4","key":"2339_CR53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00415-005-0029-3","volume":"253","author":"S Papapetropoulos","year":"2006","unstructured":"Papapetropoulos S, Singer C (2006) Improvement of cervico-trunco-brachial segmental dystonia with topiramate. J Neurol 253(4):535\u2013536","journal-title":"J Neurol"},{"issue":"6","key":"2339_CR54","first-page":"271","volume":"33","author":"S Pappa","year":"2010","unstructured":"Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S (2010) Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. ClinNeuropharmacol 33(6):271\u2013275","journal-title":"ClinNeuropharmacol"},{"issue":"2","key":"2339_CR55","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/0883073808322668","volume":"24","author":"J Rice","year":"2009","unstructured":"Rice J, Waugh Mary-Clare MC (2009) Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol 24(2):176\u2013182","journal-title":"J Child Neurol"},{"issue":"5","key":"2339_CR56","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/0883073807302601","volume":"22","author":"TD Sanger","year":"2007","unstructured":"Sanger TD, Bastian A, Brunstrom J, Damiano D, Delgado M, Dure L et al (2007) Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 22(5):530\u2013537","journal-title":"J Child Neurol"},{"key":"2339_CR57","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1212\/01.WNL.0000142083.47927.0A","volume":"4","author":"A Schiller","year":"2004","unstructured":"Schiller A, Wevers RA, Steenbergen GCH, Blau N, Jung HH (2004) Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology 4:1524\u20131527","journal-title":"Neurology"},{"issue":"1","key":"2339_CR58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF00571412","volume":"56","author":"GM Simpson","year":"1978","unstructured":"Simpson GM, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56(1):75\u201380","journal-title":"Psychopharmacology"},{"key":"2339_CR59","first-page":"19","volume":"6","author":"JW Snoek","year":"1996","unstructured":"Snoek JW, Zwarts MJ, Van WTW, Van HJJ, Der KV, Speelman JD (1996) Botulinurn toxin versus trihexyphenidyl in cervical dystonia. Neurology 6:19","journal-title":"Neurology"},{"key":"2339_CR60","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.parkreldis.2005.05.001","volume":"11","author":"KL Sullivan","year":"2005","unstructured":"Sullivan KL, Hauser RA, Louis ED, Chari G, Zesiewicz TA (2005) Levetiracetam for the treatment of generalized dystonia. Park Related Disord 11:469\u2013471","journal-title":"Park Related Disord"},{"key":"2339_CR61","doi-asserted-by":"publisher","unstructured":"Termsarasab P, Thammongkolchai T, Frucht SJ (2016) Medical treatment of dystonia. J Clin Mov Disord [Internet]. 3(1):19. Available from: http:\/\/clinicalmovementdisorders.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40734-016-0047-6","DOI":"10.1186\/s40734-016-0047-6"},{"issue":"4","key":"2339_CR62","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/ajp.147.4.445","volume":"147","author":"GK Thaker","year":"1990","unstructured":"Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 147(4):445\u2013451","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2339_CR63","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13311-013-0231-4","volume":"11","author":"MA Thenganatt","year":"2014","unstructured":"Thenganatt MA, Jankovic J (2014) Treatment of dystonia. Neurotherapeutics 11(1):139\u2013152","journal-title":"Neurotherapeutics"},{"issue":"3","key":"2339_CR64","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/mds.870130302","volume":"13","author":"RM Trosch","year":"1998","unstructured":"Trosch RM, Friedman JH, Lannon C, Smith D, Seeberger LC, Brien CFO et al (1998) Clozapine use in parkinson\u2019s disease\u202f: a retrospective analysis of a large multicentered clinical experience. Move Dis 13(3):377\u2013382","journal-title":"Move Dis"},{"issue":"6","key":"2339_CR65","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/0883073809346847","volume":"25","author":"M Vanasse","year":"2010","unstructured":"Vanasse M, Chouinard S (2010) A case of secondary dystonia responding to levodopa. J Child Neurol 25(6):780\u2013781","journal-title":"J Child Neurol"},{"issue":"2","key":"2339_CR66","first-page":"198","volume":"64","author":"C Victorri-vigneau","year":"2007","unstructured":"Victorri-vigneau C, Dailly E, Veyrac G, Jolliet P (2007) Evidence of zolpidem abuse and dependence\u202f: results of the french centre for evaluation and information on pharmacodependence (CEIP) network survey. Br J ClinPharmacol 64(2):198\u2013209","journal-title":"Br J ClinPharmacol"},{"issue":"12","key":"2339_CR67","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/mds.20233","volume":"19","author":"TA Zesiewicz","year":"2004","unstructured":"Zesiewicz TA, Louis ED (2004) Substantial improvement in a meige\u2019s syndrome patient with levetiracetam treatment. Movement Dis 19(12):2002\u20132005","journal-title":"Movement Dis"},{"issue":"3","key":"2339_CR68","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/s-0042-102884","volume":"49","author":"W Zheng","year":"2016","unstructured":"Zheng W, Xiang YQ, Ng CH, Ungvari GS, Chiu HF, Xiang YT (2016) Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry 49(3):107\u2013111","journal-title":"Pharmacopsychiatry"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-021-02339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-021-02339-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-021-02339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T20:31:51Z","timestamp":1675197111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-021-02339-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2339"],"URL":"https:\/\/doi.org\/10.1007\/s00702-021-02339-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}